Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy?

[1]  Andreas Trumpp,et al.  IFNα activates dormant haematopoietic stem cells in vivo , 2009, Nature.

[2]  F. Geissmann,et al.  Blood monocytes: development, heterogeneity, and relationship with dendritic cells. , 2009, Annual review of immunology.

[3]  Gavin Thurston,et al.  Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system , 2009, Nature Reviews Molecular Cell Biology.

[4]  D. Schadendorf,et al.  Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. , 2009, Cancer research.

[5]  Y. Yoon,et al.  Dual Angiogenic and Neurotrophic Effects of Bone Marrow–Derived Endothelial Progenitor Cells on Diabetic Neuropathy , 2009, Circulation.

[6]  I. Kasman,et al.  PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.

[7]  F. Timmermans,et al.  Endothelial progenitor cells: identity defined? , 2008, Journal of cellular and molecular medicine.

[8]  Na Zhang,et al.  Deletion of Vascular Endothelial Growth Factor in myeloid cells accelerates tumorigenesis , 2008, Nature.

[9]  Andrea Falini,et al.  Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. , 2008, Cancer cell.

[10]  J. Julien,et al.  Requirement of Myeloid Cells for Axon Regeneration , 2008, The Journal of Neuroscience.

[11]  R. Kerbel,et al.  Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. , 2008, Cancer cell.

[12]  Mikala Egeblad,et al.  Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy , 2008, Disease Models & Mechanisms.

[13]  K. Hirschi,et al.  Assessing identity, phenotype, and fate of endothelial progenitor cells. , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[14]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[15]  N. Ferrara,et al.  Role of myeloid cells in tumor angiogenesis and growth. , 2008, Trends in cell biology.

[16]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[17]  M. Danks,et al.  Stem and progenitor cell-mediated tumor selective gene therapy , 2008, Gene Therapy.

[18]  Craig Murdoch,et al.  Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. , 2008, Neoplasia.

[19]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[20]  Shahin Rafii,et al.  Migratory neighbors and distant invaders: tumor-associated niche cells. , 2008, Genes & development.

[21]  F. Peale,et al.  Bv8 regulates myeloid-cell-dependent tumour angiogenesis , 2007, Nature.

[22]  J. Pollard,et al.  Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages , 2007, Molecular oncology.

[23]  Luigi Naldini,et al.  Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state , 2007, Nature Biotechnology.

[24]  L. Naldini,et al.  Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. , 2007, Trends in immunology.

[25]  L. Naldini,et al.  Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. , 2007, Cancer research.

[26]  A. Cumano,et al.  Monitoring of Blood Vessels and Tissues by a Population of Monocytes with Patrolling Behavior , 2007, Science.

[27]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[28]  Luigi Naldini,et al.  Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. , 2007, Blood.

[29]  C. Lewis,et al.  Expression of Tie-2 by Human Monocytes and Their Responses to Angiopoietin-21 , 2007, The Journal of Immunology.

[30]  A. Sica,et al.  Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.

[31]  Yarong Wang,et al.  Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. , 2007, Cancer research.

[32]  M. Owen,et al.  Macrophage-Based Anti-Cancer Therapy: Modelling Different Modes of Tumour Targeting , 2007, Bulletin of mathematical biology.

[33]  J. Pollard,et al.  Macrophages regulate the angiogenic switch in a mouse model of breast cancer. , 2006, Cancer research.

[34]  D. Hicklin,et al.  Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors , 2006, Science.

[35]  R. Medzhitov,et al.  Type I interferons in host defense. , 2006, Immunity.

[36]  L. Naldini,et al.  Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. , 2006, Biochimica et biophysica acta.

[37]  Paolo Serafini,et al.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. , 2006, Seminars in cancer biology.

[38]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[39]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[40]  Luigi Naldini,et al.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. , 2005, Cancer cell.

[41]  C. Lewis,et al.  Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. , 2005, The American journal of pathology.

[42]  R. Galli,et al.  Tie2 identifies a hematopoietic monocytes required for tumor lineage of proangiogenic vessel formation and a mesenchymal population of pericyte progenitors , 2005 .

[43]  B. Modarai,et al.  Endothelial Progenitor Cells Are Recruited Into Resolving Venous Thrombi , 2005, Circulation.

[44]  L. Naldini,et al.  Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  Hideo Negishi,et al.  IRF-7 is the master regulator of type-I interferon-dependent immune responses , 2005, Nature.

[46]  A. Corti,et al.  Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. , 2005, Cancer research.

[47]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[48]  Keisuke Ito,et al.  Tie2/Angiopoietin-1 Signaling Regulates Hematopoietic Stem Cell Quiescence in the Bone Marrow Niche , 2004, Cell.

[49]  H. Augustin,et al.  The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. , 2004, Blood.

[50]  S. Parmar,et al.  Interferons: mechanisms of action and clinical applications , 2003, Current opinion in oncology.

[51]  L. Naldini,et al.  In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. , 2003, Human gene therapy.

[52]  L. Naldini,et al.  Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells , 2003, Nature Medicine.

[53]  N. Schmitz,et al.  Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe , 2002, Bone Marrow Transplantation.

[54]  J. Kirkwood,et al.  Interferon-alpha in tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.

[55]  G. Haines,et al.  Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue , 2002, Arthritis Research & Therapy.

[56]  Andrew V. Nguyen,et al.  Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.

[57]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[58]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[59]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[60]  Luigi Naldini,et al.  Stable knockdown of microRNA in vivo by lentiviral vectors , 2009, Nature Methods.

[61]  Dana M. Brantley-Sieders,et al.  Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. , 2009, Cancer research.

[62]  N. Ferrara,et al.  VEGF inhibition: insights from preclinical and clinical studies , 2008, Cell and Tissue Research.

[63]  G. Coukos,et al.  Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer. , 2007, Advances in experimental medicine and biology.

[64]  L. Naldini,et al.  Transduction of a gene expression cassette using advanced generation lentiviral vectors. , 2002, Methods in enzymology.

[65]  Luigi Naldini,et al.  Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics , 2001, Nature Medicine.